Melanoma
About
Mappings
NCI Thesaurus: Melanoma (coding:ncit:C3224)
OncoTree: Melanoma (coding:oncotree:MEL)
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (2) | BRAF p.V600E | Melanoma | Atezolizumab, Cobimetinib, Vemurafenib | |
| FDA (2) | BRAF p.V600K | Melanoma | Atezolizumab, Cobimetinib, Vemurafenib | |
| EMA (2) FDA (4) | BRAF p.V600E | Melanoma | Binimetinib, Encorafenib | |
| EMA (2) FDA (4) | BRAF p.V600K | Melanoma | Binimetinib, Encorafenib | |
| EMA (1) FDA (2) | BRAF p.V600E | Melanoma | Cobimetinib, Vemurafenib | |
| EMA (1) FDA (2) | BRAF p.V600K | Melanoma | Cobimetinib, Vemurafenib | |
| EMA (1) FDA (2) | BRAF p.V600E | Melanoma | Dabrafenib | |
| EMA (4) FDA (8) | BRAF p.V600E | Melanoma | Dabrafenib, Trametinib | |
| EMA (4) FDA (8) | BRAF p.V600K | Melanoma | Dabrafenib, Trametinib | |
| EMA (1) FDA (2) | BRAF p.V600E | Melanoma | Trametinib | |
| EMA (1) FDA (2) | BRAF p.V600K | Melanoma | Trametinib | |
| EMA (1) FDA (2) | BRAF p.V600E | Melanoma | Vemurafenib | |
| EMA (1) | PD-L1 < 1% | Melanoma | Nivolumab, Relatlimab | |
| EMA (1) | BRAF p.V600K | Melanoma | Dabrafenib | |
| EMA (1) | BRAF p.V600K | Melanoma | Vemurafenib |